# Papers to Acquire for VAI-MAGNIFI-CD Crosswalk Project

Generated: December 2, 2025

This document lists all identified papers with MRI scoring data for perianal Crohn's disease.
Priority papers are those most likely to contain paired VAI/MAGNIFI-CD scores or data useful for crosswalk validation.

---

## PRIORITY 1: Papers with Both VAI and MAGNIFI-CD Data

### 1. MAGNIFI-CD Original Validation Study (Spinelli et al. 2019)
- **Title:** Development and Validation of a Magnetic Resonance Index for Assessing Fistulas in Patients With Crohn's Disease
- **Authors:** Spinelli A, et al.
- **DOI:** 10.1053/j.gastro.2019.07.027
- **Year:** 2019
- **Sample Size:** n=160 (ADMIRE-CD cohort)
- **Why Valuable:** Original MAGNIFI-CD validation; compares to VAI; paired MRI scores at baseline and week 24; contains VAI/mVAI comparisons
- **Open Access:** No (paywalled at Gastroenterology)
- **Status:** ALREADY HAVE SOME DATA EXTRACTED

### 2. External Validation of MAGNIFI-CD (Beek et al. 2024)
- **Title:** External validation of the MAGNIFI-CD index in patients with complex perianal fistulising Crohn's disease
- **Authors:** Beek KJ, et al.
- **DOI:** 10.1007/s00330-024-11029-3
- **Year:** 2024
- **Sample Size:** n=65
- **Why Valuable:** External validation; compares MAGNIFI-CD to VAI and mVAI; ICC comparisons; response/remission cutoffs
- **Open Access:** Yes (PMC11836172)
- **Status:** ALREADY HAVE PDF

### 3. van Rijn Fibrosis + MAGNIFI-CD Study (2022)
- **Title:** Fibrosis and MAGNIFI-CD Activity Index at Magnetic Resonance Imaging to Predict Treatment Outcome in Perianal Fistulizing Crohn's Disease Patients
- **Authors:** van Rijn KL, et al.
- **DOI:** 10.1093/ecco-jcc/jjab157
- **Year:** 2022
- **Sample Size:** n=50
- **Why Valuable:** KEY - Has fibrosis scoring + MAGNIFI-CD; AUC 0.95; defines fibrosis as absence of hyperintensity
- **Open Access:** Yes (PMC9228904)
- **Status:** ALREADY HAVE PDF

### 4. PISA-II Trial (Long-term outcomes)
- **Title:** Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy alone for Crohn's perianal fistulas (PISA-II)
- **Authors:** Meima-van Praag EM, et al.
- **DOI:** 10.1016/j.eclinm.2023.102045
- **Year:** 2023
- **Sample Size:** n=91
- **Why Valuable:** Uses MAGNIFI-CD as primary endpoint; references VAI; radiological healing definition
- **Open Access:** Yes (eClinicalMedicine)
- **Status:** NEED TO DOWNLOAD

### 5. Modified Van Assche Index Study (Samaan et al. 2019)
- **Title:** Evaluation of the modified Van Assche index for assessing response to anti-TNF therapy with MRI in perianal fistulizing Crohn's disease
- **Authors:** Samaan MA, et al.
- **DOI:** 10.1016/j.clinimag.2019.10.010
- **Year:** 2019
- **Sample Size:** n=30
- **Why Valuable:** Compares original VAI to modified VAI; responder/non-responder scores at baseline and follow-up
- **Open Access:** No
- **Status:** NEED - Contains VAI scores we used

---

## PRIORITY 2: VAI-Only Studies (Useful for Score Distributions)

### 6. Original Van Assche Study (2003)
- **Title:** Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease
- **Authors:** Van Assche G, et al.
- **DOI:** 10.1136/gut.52.5.712
- **Year:** 2003
- **Sample Size:** n=18
- **Why Valuable:** Original VAI development; defines all score components; infliximab response data
- **Open Access:** Yes (PMC1773632)
- **Status:** NEED TO DOWNLOAD

### 7. Maintenance Anti-TNF Therapy Study (2011)
- **Title:** Fistulizing perianal Crohn's disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy
- **Authors:** Savoye-Collet C, et al.
- **DOI:** 10.1097/MIB.0b013e31821be3dc
- **Year:** 2011
- **Sample Size:** n=20
- **Why Valuable:** VAI scores before/after 1-year anti-TNF; responder/remission score changes
- **Open Access:** No
- **Status:** NEED

### 8. Pediatric VAI Study (2013)
- **Title:** MRI-based score helps in assessing the severity and in follow-up of pediatric patients with perianal Crohn disease
- **Authors:** Adler J, et al.
- **DOI:** 10.1007/s00261-013-0049-0
- **Year:** 2013
- **Sample Size:** Not specified
- **Why Valuable:** Validates VAI in pediatric population; severity groups
- **Open Access:** No
- **Status:** NEED

### 9. Infliximab MRI Effectiveness (2019)
- **Title:** Evaluating the effectiveness of infliximab on perianal fistulizing Crohn's disease by magnetic resonance imaging
- **Authors:** Xu Y, et al.
- **DOI:** 10.3748/wjg.v25.i6.718
- **Year:** 2019
- **Sample Size:** Variable
- **Why Valuable:** VAI scores pre/post 6 infliximab treatments; significant score decrease
- **Open Access:** Yes (PMC6375345)
- **Status:** NEED TO DOWNLOAD

### 10. Higher Anti-TNF Levels Study (2022)
- **Title:** Higher Anti-tumor Necrosis Factor-α Levels Correlate With Improved Radiologic Outcomes in Crohn's Perianal Fistulas
- **Authors:** Multiple
- **DOI:** 10.1016/j.cgh.2021.09.041
- **Year:** 2022
- **Sample Size:** n=193 (117 infliximab, 76 adalimumab)
- **Why Valuable:** Largest study correlating drug levels with VAI; score distributions by tertile
- **Open Access:** No
- **Status:** NEED

---

## PRIORITY 3: MAGNIFI-CD-Only Studies

### 11. MAGNIFI-CD Treatment Monitoring (ECCO 2023)
- **Title:** P296 MAGNIFI-CD index is appropriate for treatment monitoring in perianal Crohn's Disease
- **Authors:** Multiple
- **DOI:** 10.1093/ecco-jcc/jjac190.0426
- **Year:** 2023
- **Sample Size:** Variable
- **Why Valuable:** MAGNIFI-CD cutoffs for response (≤14) and remission (≤10)
- **Open Access:** Yes (Conference abstract)
- **Status:** NEED

### 12. MAGNIFI-CD Clinical Outcomes (DDW 2022)
- **Title:** Mo1465: Performance of MAGNIFI-CD Index at Follow-up MRI in Predicting Clinical Outcomes
- **Authors:** Multiple
- **Year:** 2022
- **Why Valuable:** MAGNIFI-CD predictive performance
- **Open Access:** Conference abstract
- **Status:** NEED

---

## PRIORITY 4: Stem Cell Therapy Trials (MRI Endpoints)

### 13. ADMIRE-CD Trial (Original)
- **Title:** Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease
- **Authors:** Panes J, et al.
- **DOI:** 10.1016/S0140-6736(16)31203-X
- **Year:** 2016
- **Sample Size:** n=212
- **Why Valuable:** Pivotal darvadstrocel trial; MRI-based combined remission endpoint; source of MAGNIFI-CD validation data
- **Open Access:** No
- **Status:** NEED

### 14. ADMIRE-CD Long-term Follow-up
- **Title:** Follow-up Study to Evaluate the Long-term Safety and Efficacy of Darvadstrocel
- **Authors:** Panes J, et al.
- **DOI:** 10.1093/ibd/izab106
- **Year:** 2022
- **Sample Size:** n=212 (104-week follow-up)
- **Why Valuable:** Long-term MRI outcomes; MAGNIFI-CD trajectories
- **Open Access:** No
- **Status:** NEED

### 15. ADMIRE-CD II Trial Results
- **Title:** Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas (ADMIRE-CD II)
- **Authors:** Multiple
- **DOI:** 10.1093/ecco-jcc/jjae017
- **Year:** 2024
- **Sample Size:** n=320
- **Why Valuable:** Phase 3 MRI endpoints; placebo response rates
- **Open Access:** Conference abstract (ECCO 2024)
- **Status:** NEED

### 16. Darvadstrocel Meta-Analysis (2025)
- **Title:** Darvadstrocel for complex perianal fistulas in Crohn's disease: A systematic review and meta-analysis
- **Authors:** Taxonera C, et al.
- **DOI:** 10.1002/ueg2.12673
- **Year:** 2025
- **Sample Size:** Meta-analysis
- **Why Valuable:** Pooled MRI healing rates
- **Open Access:** Yes
- **Status:** NEED TO DOWNLOAD

### 17. MSC Therapy Case Series (2024)
- **Title:** Mesenchymal stem cell therapy for therapy refractory complex Crohn's perianal fistulas: a case series
- **Authors:** Multiple
- **DOI:** 10.1186/s13287-024-03779-0
- **Year:** 2024
- **Sample Size:** Case series
- **Why Valuable:** Uses MAGNIFI-CD ≤6 as radiological remission endpoint
- **Open Access:** Yes
- **Status:** NEED TO DOWNLOAD

---

## PRIORITY 5: Ustekinumab Studies

### 18. Ustekinumab Radiological Healing Study
- **Title:** Ustekinumab Promotes Radiological Fistula Healing in Perianal Fistulizing Crohn's Disease
- **Authors:** Li D, et al.
- **DOI:** 10.3390/jcm12030939
- **Year:** 2023
- **Sample Size:** n=67 with MRI
- **Why Valuable:** VAI scores before/after ustekinumab; significant decrease (9 to 5.5)
- **Open Access:** Yes (MDPI)
- **Status:** DATA ALREADY EXTRACTED - NEED FULL PDF

### 19. Ustekinumab Real-World Analysis
- **Title:** Efficacy of Ustekinumab on perianal fistulizing Crohn's disease: a retrospective single-center real-world analysis
- **Authors:** Multiple
- **Year:** 2022
- **Sample Size:** n=89
- **Why Valuable:** VAI changes; clinical/radiological response rates
- **Open Access:** Partial
- **Status:** NEED

### 20. HEAL Study (UST vs VDZ)
- **Title:** Persistence, effectiveness and safety of ustekinumab and vedolizumab therapy for complex perianal fistula
- **Authors:** GETECCU
- **DOI:** 10.1016/j.dld.2024.05.020
- **Year:** 2024
- **Sample Size:** Comparative
- **Why Valuable:** Compares outcomes between biologics
- **Open Access:** No
- **Status:** NEED

---

## PRIORITY 6: Vedolizumab Studies

### 21. ENTERPRISE Study
- **Title:** Efficacy and Safety of 2 Vedolizumab Intravenous Regimens for Perianal Fistulizing Crohn's Disease
- **Authors:** Multiple
- **DOI:** 10.1016/j.cgh.2021.09.041
- **Year:** 2022
- **Sample Size:** n=32 with active fistulae
- **Why Valuable:** VAI score changes at week 30 (-1.1); MRI-defined outcomes
- **Open Access:** No
- **Status:** NEED

---

## PRIORITY 7: JAK Inhibitor Studies

### 22. DIVERGENCE 2 (Filgotinib)
- **Title:** Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulising Crohn's Disease
- **Authors:** Multiple
- **DOI:** 10.1093/ecco-jcc/jjae024
- **Year:** 2024
- **Sample Size:** Phase 2 RCT
- **Why Valuable:** First JAK inhibitor trial for PFCD; combined fistula response includes MRI (no collections >1cm)
- **Open Access:** Yes (PMC11147792)
- **Status:** NEED TO DOWNLOAD

### 23. Upadacitinib Post Hoc Analysis
- **Title:** Efficacy and Safety of Upadacitinib for Perianal Fistulizing Crohn's Disease
- **Authors:** Multiple
- **DOI:** 10.1016/j.cgh.2024.09.031
- **Year:** 2024
- **Sample Size:** n=143 with fistulas (from 1021 total)
- **Why Valuable:** JAK inhibitor data; drainage resolution rates
- **Open Access:** Partial
- **Status:** NEED

---

## PRIORITY 8: Pediatric Studies

### 24. PEMPAC Index (ImageKids Study)
- **Title:** Development and Validation of a Pediatric MRI-Based Perianal Crohn Disease (PEMPAC) Index
- **Authors:** Defined JL, et al.
- **DOI:** 10.1093/ibd/izab131
- **Year:** 2021
- **Sample Size:** n=80 children
- **Why Valuable:** Pediatric MRI index; correlates with adult VAI (r=0.93)
- **Open Access:** Yes (Oxford)
- **Status:** NEED TO DOWNLOAD

### 25. Pediatric MRI Predictors
- **Title:** MRI predictors of treatment response for perianal fistulizing Crohn disease in children and young adults
- **Authors:** Horsthuis K, et al.
- **DOI:** 10.1007/s00247-013-2771-5
- **Year:** 2013
- **Sample Size:** Pediatric cohort
- **Why Valuable:** Fistula length as predictor; pediatric score distributions
- **Open Access:** No
- **Status:** NEED

---

## PRIORITY 9: Reviews and Guidelines

### 26. AJR Special Series: Perianal Imaging in Crohn Disease
- **Title:** Perianal Imaging in Crohn Disease: Current Status With a Focus on MRI
- **Authors:** Multiple
- **DOI:** 10.2214/AJR.21.26615
- **Year:** 2022
- **Sample Size:** Review
- **Why Valuable:** Comprehensive review of VAI, mVAI, MAGNIFI-CD, PEMPAC; component descriptions
- **Open Access:** No
- **Status:** NEED

### 27. Role of MRI in Perianal Fistulizing Disease (2024)
- **Title:** The role of MRI in perianal fistulizing disease: diagnostic imaging and classification systems
- **Authors:** Multiple
- **DOI:** 10.1007/s00261-024-04455-w
- **Year:** 2024
- **Sample Size:** Review
- **Why Valuable:** Most recent comprehensive review; discusses all scoring systems
- **Open Access:** Yes (PMC11794340)
- **Status:** NEED TO DOWNLOAD

### 28. Radiological Outcomes Systematic Review (2020)
- **Title:** Radiological outcomes in perianal fistulizing Crohn's disease: A systematic review and meta-analysis
- **Authors:** Multiple
- **DOI:** 10.1002/ibd.28943
- **Year:** 2020
- **Sample Size:** Meta-analysis (n=259)
- **Why Valuable:** Pooled VAI outcomes across 9 studies
- **Open Access:** Yes (PMC7273731)
- **Status:** ALREADY HAVE PDF

### 29. Guide Through the Tunnel (2025)
- **Title:** A Guide Through the Tunnel: Updates in the Approach to Classification and Management of Perianal Fistulizing Crohn's Disease
- **Authors:** Multiple
- **DOI:** 10.1007/s11894-025-00998-0
- **Year:** 2025
- **Sample Size:** Review
- **Why Valuable:** Most recent management guidelines; TOpClass classification
- **Open Access:** Partial
- **Status:** NEED

---

## PRIORITY 10: Recent Conference Abstracts (ECCO/DDW 2023-2025)

### 30. P325 ECCO 2022 (Mtir et al.)
- **Title:** AUROC Comparison: VAI vs mVAI vs MAGNIFI-CD for Treatment Response
- **Authors:** Mtir M, et al.
- **Year:** 2022
- **Sample Size:** n=38
- **Why Valuable:** KEY - Direct AUROC comparison: VAI=0.925, mVAI=0.908, MAGNIFI-CD=0.869
- **Open Access:** Conference abstract
- **Status:** DATA EXTRACTED - NEED FULL ABSTRACT

### 31. OP17 ECCO 2025 - Radiological Healing Definition
- **Title:** Defining radiological healing in perianal fistulising Crohn's Disease: a global modified Delphi consensus
- **Authors:** Multiple
- **DOI:** 10.1093/ecco-jcc/jjaf017
- **Year:** 2025
- **Sample Size:** 84 experts, 16 countries
- **Why Valuable:** Consensus definition: absence of T2-hyperintensity
- **Open Access:** Conference abstract
- **Status:** NEED

---

## PRIORITY 11: Additional Studies to Search

### 32. MRI Deep Remission Study
- **Title:** Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease
- **Authors:** Multiple
- **DOI:** 10.3748/wjg.v23.i23.4284
- **Year:** 2017
- **Sample Size:** Variable
- **Why Valuable:** MRI predictors of deep remission
- **Open Access:** Yes (PMC5483503)
- **Status:** NEED TO DOWNLOAD

### 33. TOpClass Classification Application
- **Title:** TOpCLASS Expert Consensus Classification of Perianal Fistulising Crohn's Disease: A Real-world Application
- **Authors:** Multiple
- **DOI:** 10.1093/ecco-jcc/jjae069
- **Year:** 2024
- **Sample Size:** Serial MRI cohort
- **Why Valuable:** New classification system; real-world MRI data
- **Open Access:** Yes
- **Status:** NEED TO DOWNLOAD

### 34. Modified Van Assche Index Development
- **Title:** Modified Van Assche magnetic resonance imaging-based score for assessing the clinical status of anal fistulas
- **Authors:** Multiple
- **Year:** 2020
- **Sample Size:** Variable
- **Why Valuable:** mVAI scoring system; Pearson correlation 0.547 with clinical status
- **Open Access:** Yes (PMC7440082)
- **Status:** NEED TO DOWNLOAD

---

## Summary Statistics

| Category | Count | Already Have | Need to Get |
|----------|-------|--------------|-------------|
| Both VAI + MAGNIFI-CD | 5 | 3 | 2 |
| VAI-only studies | 5 | 0 | 5 |
| MAGNIFI-CD-only | 2 | 0 | 2 |
| Stem cell trials | 5 | 0 | 5 |
| Ustekinumab | 3 | 1 (partial) | 2 |
| Vedolizumab | 1 | 0 | 1 |
| JAK inhibitors | 2 | 0 | 2 |
| Pediatric | 2 | 0 | 2 |
| Reviews | 4 | 1 | 3 |
| Conference abstracts | 2 | 1 (partial) | 1 |
| Additional | 3 | 0 | 3 |
| **TOTAL** | **34** | **6** | **28** |

---

## Download Priority Queue

### Immediate Priority (Open Access - Download Now):
1. PISA-II Trial (eClinicalMedicine) - OA
2. Original Van Assche 2003 (PMC1773632) - OA
3. Infliximab MRI 2019 (PMC6375345) - OA
4. Darvadstrocel Meta-Analysis 2025 - OA
5. MSC Case Series 2024 - OA
6. DIVERGENCE 2 Filgotinib (PMC11147792) - OA
7. PEMPAC Index - OA
8. MRI Role Review 2024 (PMC11794340) - OA
9. MRI Deep Remission 2017 (PMC5483503) - OA
10. TOpClass 2024 - OA
11. Modified VAI 2020 (PMC7440082) - OA

### Request from Authors/Institutional Access:
1. MAGNIFI-CD Original (Gastroenterology 2019) - Contains full validation data
2. Samaan mVAI Study 2019 - VAI scores we used
3. Higher Anti-TNF Levels 2022 - n=193 largest VAI dataset
4. ADMIRE-CD Original + Follow-up - Source of MAGNIFI-CD data
5. ENTERPRISE Vedolizumab - VAI changes

### Conference Abstracts (Available through ECCO/DDW):
1. P325 ECCO 2022 (Mtir) - AUROC comparison
2. OP17 ECCO 2025 - Healing definition consensus
3. P296 ECCO 2023 - MAGNIFI-CD cutoffs

---

## Notes

- Papers marked "DATA EXTRACTED" have had summary statistics incorporated into our crosswalk formula
- Paywalled papers may be accessible through institutional subscriptions or interlibrary loan
- Conference abstracts often have limited data but can confirm score ranges and correlations
- Priority should be given to papers with patient-level data or multiple timepoint measurements
